New IV drug shows promise for kids with stubborn arthritis

NCT ID NCT02277444

First seen Nov 15, 2025 · Last updated May 08, 2026 · Updated 19 times

Summary

This study tested a drug called golimumab in 130 children with active juvenile idiopathic arthritis that did not improve with methotrexate. The drug is given through a vein and works by blocking a protein that causes inflammation. The main goal was to see how the drug moves through the body and to check its safety over 52 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARTHRITIS, JUVENILE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Study site

    San Diego, California, United States

  • Study site

    Chicago, Illinois, United States

  • Study site

    Boston, Massachusetts, United States

  • Study site

    Hackensack, New Jersey, United States

  • Study site

    New Hyde Park, New York, United States

  • Study site

    Durham, North Carolina, United States

  • Study site

    Hickory, North Carolina, United States

  • Study site

    Avon, Ohio, United States

  • Study site

    Cincinnati, Ohio, United States

  • Study site

    Cleveland, Ohio, United States

  • Study site

    Portland, Oregon, United States

  • Study site

    Philadelphia, Pennsylvania, United States

  • Study site

    Austin, Texas, United States

  • Study site

    Salt Lake City, Utah, United States

  • Study site

    Buenos Aires, Argentina

  • Study site

    Rosario, Argentina

  • Study site

    San Miguel de Tucumán, Argentina

  • Study site

    Botucatu, Brazil

  • Study site

    Campinas, Brazil

  • Study site

    Porto Alegre, Brazil

  • Study site

    Rio de Janeiro, Brazil

  • Study site

    São Paulo, Brazil

  • Study site

    Calgary, Alberta, Canada

  • Study site

    Toronto, Ontario, Canada

  • Study site

    Montreal, Quebec, Canada

  • Study site

    Región Metropolitana de Santia, Chile

  • Study site

    Haifa, Israel

  • Study site

    Kfar Saba, Israel

  • Study site

    Petah Tikva, Israel

  • Study site

    Chihuahua City, Mexico

  • Study site

    Guadalajara, Mexico

  • Study site

    Mexico City, Mexico

  • Study site

    Mosco2, Russia

  • Study site

    Saint Petersburg, Russia

  • Study site

    Saratov, Russia

  • Study site

    Tolyatti, Russia

  • Study site

    Ufa, Russia

  • Study site

    Cape Town, South Africa

Conditions

Explore the condition pages connected to this study.